Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Atogepant (Qulipta) and erenumab (Aimovig) are both medications used to prevent migraines in adults, and they belong to the class of calcitonin gene-related peptide (CGRP) receptor blockers. However, they differ in several ways. Atogepant is taken orally once a day, while erenumab is administered as an injection under the skin once a month. Both medications are available only as brand-name products, with no generic versions currently available. Common side effects of atogepant include nausea, constipation, and sleepiness, whereas erenumab may cause pain at the injection site, constipation, and high blood pressure. Additionally, atogepant can interact with many medications, such as rifampin (Rifadin) and clarithromycin. It's important to discuss with a healthcare professional which medication might be best for you based on your needs and medical history.
Qulipta (atogepant)
Aimovig (erenumab)
Qulipta (atogepant)
Aimovig (erenumab)
Summary of Qulipta vs. Aimovig
Summary for Calcitonin gene-related peptide (CGRP) receptor blocker
Prescription only
Qulipta (atogepant) is a medication that's used to prevent migraines in adults. The specific dosing will depend on how many migraines you have per month, but the medication is typically taken once daily. Qulipta (atogepant) is currently brand only; it isn't available as a lower-cost generic yet. Side effects include nausea, constipation, and sleepiness.
Summary for CGRP antagonist
Prescription only
Aimovig (erenumab or erenumab-aooe) is a migraine medication called a CGRP antagonist. It helps prevent migraines in adults. Aimovig (erenumab) comes as an autoinjector and prefilled syringe. You inject each dose under the skin in the thigh or stomach once a month. Side effects can include pain, swelling, or redness where you injected the medication.